Consensus Jasper Therapeutics, Inc.

Equities

JSPR

US4718712023

Real-time Estimate Cboe BZX Other stock markets 10:06:52 10/05/2024 pm IST			5-day change	1st Jan Change
21.19 ^USD	-1.07%		-13.56%	+168.63%

07/05	Certain Restricted Stock Units of Jasper Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.	CI
07/05	Certain Stock Options of Jasper Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.	CI

Evolution of the average Target Price on Jasper Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

d29a2.ROK1WXqyKE1-Koc9D7GwES5Hz4Pnpw3NvC-bogOpJ5A.HbuDMD37bSscc7RLWMuJS0Uh-9PU7nie6X_dzlTkVdwJh80WMvpfHC8e8A~6503c2ddd7206d742d58f09ec89b5f32

Analyst Recommendations on Jasper Therapeutics, Inc.

HC Wainwright Starts Jasper Therapeutics With Buy Rating, $65 Price Target	06/05	MT
Evercore ISI Initiates Jasper Therapeutics With Outperform Rating, Price Target is $65	03/04	MT
Jasper Therapeutics Initiated at Outperform, Speculative Risk by RBC, Price Target Set at $70 Amid Bullish View on Lead Asset	28/03	MT
TD Cowen Initiates Jasper Therapeutics With Outperform Rating	18/03	MT
Capital One Initiates Jasper Therapeutics With Overweight Rating, $7 Price Target	11/23/11	MT
EF Hutton Assumes Jasper Therapeutics at Buy With $6.85 Price Target	25/23/25	MT
EF Hutton Raises Price Target on Jasper Therapeutics to $6.85 From $4, Maintains Buy Rating	16/23/16	MT
Credit Suisse Lowers Jasper Therapeutics' PT to $3 From $7 After Announcing Pipeline Reprioritization, Keeps Outperform Rating	11/23/11	MT
Oppenheimer Adjusts Jasper Therapeutics Price Target to $8 From $21, Maintains Outperform Rating	14/22/14	MT
EF Hutton Starts Jasper Therapeutics at Buy With $4 Price Target	01/22/01	MT
Credit Suisse Lowers Jasper Therapeutics' Price Target to $8 from $9 on Moderately Tempered Peak Market Share Assumption, Keeps Outperform Rating	13/22/13	MT
Cantor Fitzgerald Starts Jasper Therapeutics at Overweight With $10 Price Target	28/22/28	MT
Credit Suisse Trims Jasper Therapeutics' Price Target to $10 from $15, Keeps Outperform Rating	25/22/25	MT
Credit Suisse Starts Jasper Therapeutics at Outperform with $15 Price Target	08/21/08	MT
JASPER THERAPEUTICS : William Blair Initiates Jasper Therapeutics at Outperform Rating	21/21/21	MT
JASPER THERAPEUTICS : BMO Initiates Jasper Therapeutics at Outperform Rating With $19 Price Target	20/21/20	MT
Jasper Therapeutics : Shares Soar Midday After Initiated by Oppenheimer With Outperform Rating, $21 Price Target	13/21/13	MT
JASPER THERAPEUTICS : Oppenheimer Starts Jasper Therapeutics at Outperform with $21 Price Target	13/21/13	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

21.42 USD

Average target price

64.17 USD

Spread / Average Target

+199.56%

High Price Target

80 USD

Spread / Highest target

+273.48%

Low Price Target

50 USD

Spread / Lowest Target

+133.43%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Jasper Therapeutics, Inc.

HC Wainwright
Evercore ISI
RBC Capital Markets
TD Cowen
Capital One Securities
EF Hutton
Credit Suisse
Oppenheimer
Cantor Fitzgerald
William Blair & Co.
BMO Capital

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar